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Endometrial cancer is the most common gynaecological cancer in western countries. Radiotherapy remains the mainstay
of postoperative management, but accumulating data show that adjuvant chemotherapy may display promising results after
staging surgery. The prognosis of patients with metastatic disease remains disappointing with only one-year survival. Progestins
represent an eﬀective option, especially for those patients with low-grade estrogen and/or progesterone receptor positive disease.
Chemotherapyusingthecombinationofpaclitaxel,doxorubicin,andcisplatinisbeneﬁcialforpatientswithadvancedormetastatic
disease after staging surgery and potentially for patients with early-stage disease and high-risk factors. Toxicity is a point in
question; however, the combination of paclitaxel with carboplatin may diminish these concerns. In women with multiple medical
comorbidities, single-agent chemotherapy may be better tolerated with acceptable results. Our increased knowledge of the
molecular aspects of endometrial cancer biology has paved the way for clinical research to develop novel targeted antineoplastic
agents (everolimus, temsirolimus, geﬁtinib, erlotinib, cetuximab, trastuzumab, bevacizumab, sorafenib) as more eﬀective and
less toxic options. Continued investigation into the molecular pathways of endometrial cancer development and progression will
increase our knowledge of this disease leading to the discovery of novel, superior agents.
1.Introduction
Endometrial cancer is the most prevalent gynecological
cancer in the Western World representing the third com-
monest cancer aﬀecting women. By contrast, the incidence
in the non-Western World is approximately tenfold lower
[1]. The excellent prognosis of early-stage endometrial
cancer renders it one of the most curable gynecologi-
cal malignancies. Radiotherapy remains the mainstay of
postoperative management, but accumulating data show
that adjuvant chemotherapy may display promising results
after staging surgery. The term staging surgery implies to
hysterectomy, bilateral salpingoophorectomy, and pelvic and
para-aortic node dissection with or without omentectomy.
Unfortunately, the prognosis of patients with metastatic
disease remains disappointing with only one-year survival
commonly reported despite treatment eﬀorts [2].
Systemic interventions play a key role in the treatment
of advanced/metastatic and relapsed endometrial cancer.
Progestins remain an eﬀective option, especially for those
patients with low-grade estrogen and/or progesterone recep-
tor positive disease, some of whom achieve prolonged
survival [3–14]. Platinum compounds, anthracyclines, and
more recently taxanes have been developed in combination
regimens, achieving response rates exceeding 50% and
resulting in more than one-year survival in randomized
trials [2, 15–40]. Today, the combination of doxorubicin
45mg/m2, cisplatin 50mg/m2, and paclitaxel 160mg/m2
(TAP) [29] is considered the most eﬀective chemotherapy
regimen for advanced or recurrent endometrial cancer. A
large GOG trial which is currently evaluating TAP against
paclitaxelandcarboplatinmayatlastprovideconclusivedata
onthecomparativeeﬃcacyofthelesstoxicnonanthracycline
combination [2]. It is worth mentioning that the GOG2 Obstetrics and Gynecology International
209 trial has closed to accrual, although results are not yet
available.
Adjuvant chemotherapy using the same agents is beneﬁ-
cial for patients with advanced disease after staging surgery
and potentially for patients with early-stage disease and
high-risk factors, such as high-grade or nonendometrioid
histology. Their combination with radiotherapy is still under
debate. Toxicity is a point in question for endometrial
cancer patients treated with chemotherapy, given their often
advanced age and multiple comorbidities. Hematologic
toxicity, cardiac toxicity, and neurotoxicity probably present
more cause for concern, as they can increase the risk
of treatment-related death or long-term disabilities. The
development of less toxic regimens such as the combination
of paclitaxel with carboplatin may diminish these concerns.
Our increased knowledge of the molecular aspects of
endometrial cancer biology has paved the way for clinical
research to develop novel targeted antineoplastic agents as
more eﬀective and less toxic options. This review article
aims to present the gathering evidence of current adjuvant
systemic treatment of endometrial cancer in an attempt to
direct ongoing clinical research.
2. AdjuvantChemotherapy
Radiotherapy (vaginal brachytherapy and/or pelvic irradia-
tion) remains the mainstay of postoperative management,
decreasing the rate of pelvic recurrences. Moreover, it is the
preferred sole method of treatment for patients with high-
risk and may be intermediate-risk early-stage disease [41–
43]. Additionally, it is worth mentioning that trials in early-
stage disease have shown decreased locoregional recurrence
but no improvement in survival with radiotherapy. The
use of adjuvant systemic treatment in endometrial cancer
is an individualised decision based on the assessment of
prognostic factors which increase the potential for relapse
and distant metastasis such as stage, age >70 years, and
histological characteristics (grade, serous or clear cell type,
lymphovascular space invasion) [42, 44]. The anticipated
beneﬁtsandrisksfortoxicityarealsotakenintotheequation.
Grade 3 endometrioid tumours, as well as the serous and
clear cell variants, display a more aggressive behaviour
than grades 1 and 2 endometrioid cancers. These high-risk
types are commonly diagnosed as advanced or metastatic
disease but early-stage cancers can also result in similarly
unfavourable outcomes [45]. Surgical staging procedures
also play a signiﬁcant role, since a recurrence risk for a
proportion of patients with ostensible stage I disease and
high-risk histology may be underestimated [45, 46].
Although current evidence does not support the use of
progestins in the adjuvant treatment of endometrial cancer
[47, 48], chemotherapy may prove beneﬁcial in patients
with high-risk features. Three randomised trials comparing
chemotherapywithradiotherapyforhigh-andintermediate-
risk endometrial cancer have produced somewhat equivocal
but important results (Table 1).
Randall et al. reported the results of the GOG pro-
tocol 122 which randomized 396 women with stage III
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Figure 1: Postoperative whole abdominal radiotherapy versus
combination doxorubicin-cisplatin chemotherapy in advanced
endometrial carcinoma. ∗30-Gy in fractions with a 15-Gy boost.
and optimally debulked stage IV endometrial cancer to
postoperatively receive either whole abdominal irradiation
(WAI) or chemotherapy with cisplatin and doxorubicin
(Figure 1). This study favoured chemotherapy with a hazard
ratio for progression of 0.71 and 0.68 for death, and ﬁve-year
survival rate of 55% versus 42%, respectively [49]. Another
trial included 345 intermediate- and high-risk patients
(stage IC grade 3, stage II grade 3 with >50% myometrial
invasion, and stage III) who were randomized to receive
adjuvant chemotherapy with cisplatin, doxorubicin, and
cyclosphosphamide (CAP) or external beam radiotherapy
(pelvic and paraortic). Similar results in overall and disease-
free survival were reported for both arms. The authors
notedthatradiotherapydidimprovelocalrelapserates,while
chemotherapy improved the risk for distance metastases
[50]. The latest published study comparing chemotherapy
with radiotherapy randomized 385 patients with >50%
myometrial invasion, 61% of whom had stage I disease, to
receive either CAP or external beam pelvic radiotherapy.
Although the 5-year OS and PFS rates were similar in both
arms, a signiﬁcant improvement of PFS (HR = 0.44) and OS
(HR = 0.24) was observed with chemotherapy in a subgroup
comprising patients with stage IC and >70 years old, stage
IC and grade 3 endometrioid tumors, stage II, and stage IIIA
(positive cytology) [51]. Interestingly, no signiﬁcant increase
in adverse eﬀects was observed in the CAP group versus the
radiotherapy group.
Single modality adjuvant treatment with chemotherapy
entails a high risk of local relapse. Indeed, 36% of the
initial recurrences were limited to the pelvis in the GOG
122 study [49]. This presents a strong argument for the
implementation of combined modality treatments. Never-
theless, salvage external beam radiotherapy in previously
nonirradiated patients with locoregional recurrence has
resulted in ﬁve-yearlocal control rate of 54%, disease speciﬁc
survival of 51%, and overall survival of 44% [42]. Conse-
quently, radiotherapy could be considered in later stages of
management rather than postoperatively with less risk for
combined toxicities. In the RTOG 9708 study, 46 patientsObstetrics and Gynecology International 3
Table 1: Trials on adjuvant treatment for endometrial cancer.
Author(s) Setting Pts Treatment arms 5-year PFS1 5-year OS2
Comments
(Stage) (No.) (%) (%)
Randall et al. [49] III-IV 396 WAI3 38 42 Treatment related deaths AP: 8
(4%), WAI: 5 (2%) (optimally debulked) AP4 50 55
Maggi et al. [50] ICG3-III 345
External beam 63 69
XRT5
CAP6 63 66
Susumu et al. [52] >50% myometrial
invasion
385 Pelvic XRT 83.5 85.3 Superiority of CAP in
high/intermediate risk
(stICG3-IIIA) patients
CAP 81.8 86.7
Hogberg et al. [53] IC-IIIC 367 Relvic XRT +/− BT7 75 NR8
(conﬁned to pelvis) Pelvic RT +/− BT + Cx9 82 NR
Kuoppala et al. [51] IAG3-IIIA 156
Pelvic XRT 18+ months 84.7 Intestinal complications
demanding surgery
Pelvic XRT + CEP10 25+ months 82.1 XRT: 2 (2.7%), Pelvic XRT +
CEP: 8 (9.5%)
1PFS, progression-free survival; 2OS, overall survival; 3WAI, whole abdominal irradiation; 4AP, doxorubicin and cisplatin; 5XRT, irradiation; 6CAP,
cyclophosphamide, doxorubicin and cisplatin; 7BT, vaginal brachytherapy; 8NR, not reported; 9Cx, chemotherapy with AP or paclitaxel, epirubicin and
carboplatin or paclitaxel and carboplatin; 10CEP, cyclophosphamide, epirubicin and cisplatin.
with endometrial cancer conﬁned to the pelvis (stage I to
IIIC) displaying adverse histological prognostic factors were
treated with chemo-radiotherapy followed by chemotherapy
with cisplatin and paclitaxel. The 5-year DFS and OS rates
for stage III patients were 72% and 77%, respectively,
and no relapses in stage I or II patients were recorded.
However, a grade 4 long-term toxicity was reported in 4%
of patients [54]. The NSGO-EC-9501/EORTC 55991 study
randomized 372 patients with high-risk endometrial cancer
(grade 3, deep myometrial invasion, DNA nondiploidy,
serous, clear-cell, or anaplastic histology) of surgical stages
I to IIIC and without paraortic lymph node involvement
to receive either external beam irradiation with or without
vaginal brachytherapy, or radiotherapy plus platinum-based
chemotherapy. The results favoured the combined modality
treatment with an HR of 0.58 for PFS [53]. Nevertheless,
another recently published study of sequential chemo-
radiotherapy (cyclophosphamide, cisplatin, epirubicin) ver-
sus radiotherapy alone in 157 patients, with stage IA/B,
grade 3 and stages IC to IIIA of any grade, failed to show
a statistically signiﬁcant improvement in survival outcomes.
Furthermore, chemotherapy seemed to increase intestinal
toxicity requiring surgery [51].
It has become clear that questions surrounding adju-
vant chemotherapy in endometrial cancer and its optimal
application are far from being settled and hence form an
active ﬁeld of clinical research. The use of newer agents,
such as paclitaxel, appears promising. Its combination with
carboplatin has shown favourable eﬃcacy and toxicity as
adjuvant treatment of endometrial cancer [55]a n dm a y
prove to be a valid and less toxic option to anthracycline-
platinum combinations. GOG protocol 184 (Figure 2)d e a l s
with advanced stage patients randomized after surgery with
optimal debulking (diameter ≤2cm) and tumor-directed
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Figure 2: Recent randomized GOG trials of postoperative radio-
therapy and/or combination chemotherapy in endometrial cancer.
∗Both arms received G-CSF. ∗∗Paclitaxel was administrated on
day 2.4 Obstetrics and Gynecology International
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Figure 3: Chemotherapy and radiation therapy compared with
radiation therapy alone in treating patients with high-risk stage
I, stage II, or stage III endometrial cancer. ∗Patients with cervical
involvement undergo vaginal brachytherapy.
radiation to cisplatin and doxorubicin with or without pacli-
taxel. There was no statistically signiﬁcant improvement in
recurrence free survival between the two regimens. Overall,
the addition of paclitaxel had little impact on recurrence
free survival and was associated with increased morbidity.
Of note, subset analysis revealed a 50% reduction in the
risk of recurrence or death for patients with gross residual
disease in the triplet arm when compared to the doublet
one [56]. The advantages of identifying early-stage patients
whomaybeneﬁtfromadjuvantchemotherapyarethesubject
of GOG 194 (Figure 2) and PORTEC-3 (Figure 3) trials,
evaluating the addition of paclitaxel and either cisplatin or
carboplatin to adjuvant radiotherapy. Notably, the aggressive
nature of serous and clear cell tumours and a wealth of
data from nonrandomized studies [30–41, 54, 57–67]h a v e
led many institutions to standardize adjuvant chemotherapy
for all early-stage patients with such histology. However,
the small volume of patients belonging to these subgroups
(2%–4% of stage I endometrial cancer) hampers the design
of a phase III study to further clarify the merits of this
approach.
3. Toxicity of Systemic Chemotherapy for
EndometrialCancerandPatientSelection
Patients with endometrial cancer often present cause for
concern due to toxicity, given that they are often of
advanced age, with poor performance status and multiple
comorbidities.Thesigniﬁcanceofageandcoexistingmedical
conditions in clinical decision-making can be extrapolated
from the observation that 40% of deaths in patients partic-
ipating in clinical trials are attributed to conditions other
than endometrial cancer [41]. Whilst it is true that more
intensive combination regimens achieved greater eﬃcacy
in advanced or recurrent endometrial cancer, toxicity was
unfortunately increased. Even among selected populations
of phase II or III trials, treatment-related deaths are not
uncommon despite the use of G-CSF [25–27, 29, 35]. A
meta-analysis of pooled toxicity data from ﬁve randomized
trials [17–19, 29, 68] comparing less intensive with more
intensive chemotherapy showed that treatment intensiﬁca-
tion resulted in higher rates of severe (grades 3 and 4)
nausea and vomiting, gastrointestinal toxicity, thrombocy-
topenia,infection,renaltoxicity,andneurotoxicitywithodds
ratios of 2.73, 2.48, 4.44, 4.36, 3.55, and 5.81, respectively
[15].
Toxicity far outweighs any concerns in the adjuvant
setting. In the phase III trial comparing WAI with AP
chemotherapy for stage III/IV endometrial cancer after
staging surgery, 13 treatment-related deaths were reported
among 396 randomized patients, most of which involved
the chemotherapy arm. Severe hematologic toxicity was
documented in 88% of patients on AP as opposed to
14% of those on WAI arm [49]. Furthermore, 17% of
patients receiving AP discontinued treatment due to toxicity,
compared to only 3% treated with WAI. Maggi et al. [50]
reportedarateof35%forgrades3and4neutropeniainstage
IC-III patients receiving adjuvant CAP as opposed to a 16%
rate of severe gastrointestinal toxicity in patients treated with
radiotherapy [50]. Gastrointestinal toxicity may be more
frequently observed in patients receiving both radiotherapy
and chemotherapy, as reported by Kuoppala et al. [51],
wheretheadditionofthecyclophosphamide,epirubicin,and
cisplatin (CEP) regimen to pelvic irradiation increased the
rate of gastrointestinal complications requiring surgery from
2.7% to 9.5%.
Sincepreviouspelvicirradiation depletesthehematopoi-
etic stem cell pool and increases the potential for severe
hematologic toxicity, such patients have habitually received
lower doses of chemotherapy in phase III trials [17, 29,
35]. Albeit G-CSF support may improve the tolerability of
doublet and triplet regimens, grade 4 neutropenia remains
n o t a b l yf r e q u e n ta to v e r3 5 %[ 29, 35].
Elderly patients with predisposing factors or preex-
isting cardiac disease about to be treated with anthra-
cycline based chemotherapy are a source of concern for
cardiotoxicity. Patients enrolled in studies are routinely
screened for left ventricular function defects and those with
preexisting dysfunction or active coronary heart disease
are typically excluded [17–19, 23, 29]. Finally, patients
with longstanding diabetes mellitus may be more prone to
neurotoxicity, a debilitating condition commonly associated
with combinations including cisplatin and/or paclitaxel
[20–22, 26].
The use of prophylactic G-CSF, as well as the use of
single-agent chemotherapy or less toxic regimens, such as
thecombinationofcarboplatinwithpaclitaxelorcarboplatin
with liposomal doxorubicin, is reasonable options to be
considered for improved tolerability.
Overall,researchdatashouldbeinterpretedwithcaution.
Populations treated in studies are very likely to diﬀer from
the average population encountered in common clinical
practice; quality of life factors must be considered in the
individualization of management decisions.Obstetrics and Gynecology International 5
4. Targeted Therapy for Endometrial Cancer
4.1. Genetic Alterations in Endometrial Cancer. Nowadays,
we have a better understanding of molecular character-
istics of endometrial cancer which seem to concur with
previously established clinical and histological disease types
(Table 2)[ 69–79]. The importance of angiogenesis has been
recognised in regard to the natural history of endome-
trial cancer and presents potential clinical and therapeutic
implications. Tumor suppressor protein PTEN (phosphatase
and tensin homolog deleted on chromosome ten), a lipid-
protein phosphatase key to the regulation of normal cell
function, has been reported to be altered in up to 83% of
endometrioid carcinomas [76, 80, 81]. PTEN inactivation
is most commonly caused by mutations in both alleles
resulting in the complete loss of function (reviewed in
[76, 80]). It principally targets and dephosphorylates 3, 4,
5-trisphosphoinositides resulting in the inhibition of the
phosphatidylinositol-3 kinase (PI3K) pathway [82]. Total
lack or impairment of PTEN protein from cancer cells causes
hyperactivationofthePI3Kpathway,leadingtouncontrolled
function of several kinases, including the serine/threonine
kinase mTOR (mammalian target of rapamycin) (reviewed
in [80]). PI3KCA mutation is seen in 36% of endometri-
oid endometrial cancers and is most common in tumors
that also bear the PTEN mutation [83]. Additionally, the
upregulation of proapoptotic mechanisms involving AKT-
dependent mechanisms is mediated through PTEN, as is
the downregulation of antiapoptotic mechanisms through
Bcl-2 [84]. Since the protein phosphatase activity of PTEN
is involved in the inhibition of focal adhesion formation, cell
spread, and migration, as well as the inhibition of growth
factor-stimulated MAPK signaling, a failed or altered PTEN
expression can result in aberrant cell growth and apoptotic
escape (reviewed in [76]).
Microsatellite instability (MSI) [85], speciﬁc mutations
of K-ras [86], and β-catenin genes [87] are other genetic
alterations in endometrioid endometrial cancer. Microsatel-
lites are short segments of repetitive DNA bases scattered
throughout the genome predominantly found in noncoding
DNA. MSI, reported in 20% of sporadic endometrioid
endometrialcancers,iscausedbyinactivationofanynumber
of intranuclear proteins comprising the mismatch repair
system, leading to an accumulation of structural changes
in coding and noncoding repetitive elements of many
genes [85]. Higher rates of mutations in the PTEN gene
have been described in tumors displaying MSI as opposed
to those that do not, suggesting that PTEN could be a
target for mutations in a deﬁcient DNA repair setting
[88].
β-catenin, a component of the E-cadherin unit of
proteins, plays an important role to cell diﬀerentiation,
maintenance of normal tissue architecture, and to signal
transduction. It also acts as a downstream transcriptional
activator in the Wnt signal transduction pathway. These
mutations result in stabilization of protein that resists degra-
dation through the ubiquitin-proteasome pathway, leading
to cytoplasmic and nuclear accumulation and constitutive
target gene activity (reviewed in [76, 89, 90]).
Mutationsinp53arepresentinabout90%oftumorsand
constitute the most common genetic alterations in type 2
serous carcinomas [86]. After DNA damage, nuclear p53
accumulates and causes cell cycle arrest by inhibiting cyclin-
D1 phosphorylation of the Rb gene, thereby promoting
apoptosis [89]. Mutated p53 results in a nonfunctional
protein that accumulates in the cell and acts as a double
negative inhibitor of the wild-type p53, leading to propaga-
tion of aberrant cells. It has been suggested that mutation
in one allele occurs during early development of serous
carcinoma, and loss of the second normal allele occurs late
in the progression to carcinoma. Other frequent genetic
alterationsintype2endometrialcancersincludeinactivation
of p16 and overexpression of HER-2/neu [89]. Inactivation
of p16 tumor suppressor gene, that encodes for a cell cycle
regulatory protein, leads to uncontrolled cell growth and has
been identiﬁed in 45% of serous carcinomas and some clear
cell cancers (reviewed in [76]). HER-2/neu is an oncogene
that codes for a transmembrane receptor tyrosine kinase
involved in cell signaling. HER-2 overexpression and gene
ampliﬁcation have been found in 45% and 70% of serous
carcinomas, respectively [91].
4.2. Molecularly Targeted Therapy
4.2.1. mTOR Inhibitors. The activation of the PI3K/AKT/
mTOR signalling pathway triggered by the loss of function
of PTEN gene suggests a therapeutic role for the mammalian
target of rapamycin (mTOR) inhibition. Chemotherapy-
na¨ ıve endometrial cancer patients treated with temsirolimus,
an mTOR inhibitor, achieved a preliminary response rate of
26% according to the National Cancer Institute of Canada;
this result was not correlated to PTEN status as evaluated
by immunohistochemistry [92]. Preliminary studies of other
mTOR inhibitors, everolimus and AP2357, have shown
clinical responses mainly in the form of stable disease (8 of
15 and 7 of 19 women, resp.) [93–95]. A phase II trial of
temsirolimus in heavily pretreated patients with endometrial
cancer, recently completed by the NCIC, reported a 7%
partial response rate and a 44% stable disease rate [96]. It
should be noted that the trials of everolimus and AP2357
were both in pretreated patients. Combinations of mTOR
inhibitors with hormonal therapy, chemotherapy, or other
targeted therapies such as epidermal growth factor receptor
(EGFR) inhibitors and antiangiogenic agents have shown
such promise, in the preclinical setting, that numerous
trials are currently underway to develop and test such
combinations; temsirolimus is being tested with topotecan,
bevacizumab and progestin therapy (reviewed in [80]). It
has been shown that exposure of endometrial cancer cell
lines to an mTOR inhibitor increases progesterone mRNA
expression and inhibits ER mRNA expression (reviewed in
[80], [97]).
4.2.2. Human Epidermal Growth Factor Receptor (EGFR) or
HER Family Inhibition
EGFR Inhibitors. EGFR is commonly expressed in normal
endometrium, but its overexpression in endometrial cancer6 Obstetrics and Gynecology International
Table 2: Types of endometrial cancer according to the Bokhman model and correlations with clinicopathological and molecular character-
istics.
Characteristics Type I tumors Type II tumors
Clinicopathological
Incidence ∼80% ∼20%
Age at initial diagnosis Pre/peri-menopausal Postmenopausal
Histology Endometrioid
Non-endometrioid
(predominantly serous and
clear cell)
Grade Usually low Usually high
Premalignant phase Atypical hyperplasia Glandular dysplasia (for
serous tumours)
Predisposing factors Obesity, prolonged estrogen
exposure
ER, PgR >90% 0–31%
Molecular
HER-2/neu (overexpression) 3% 18%
EGFR expression 46% 34%
P53 mutations 5–10% 80–90%
Ploidy 67% diploid 45% diploid
PTEN (loss of function through deletion or mutation) 50–80% 10–11%
P16 inactivation 10% 40%
K-ras (mutational activation) 13–26% 0–10%
E-cadherin (reduced or non expression) 10–20% 62–87%
β-catenin CTNNB1 (gain of function mutation) 25–38% Rare
is associated with advanced stage and poor prognosis [98–
103]. Antagonists to EGFR include small molecule tyro-
sine kinase inhibitors (geﬁtinib, erlotinib, and lapatinib)
and the anti-EGFR monoclonal antibody cetuximab. The
use of erlotinib in women with recurrent and metastatic
endometrial cancer was not promising with only 1 partial
response among 27 women [104]. A phase II clinical trial of
cetuximab in recurrent endometrial cancer is still ongoing. It
is hoped that other new therapies will succeed in targeting
speciﬁc known molecular defects in endometrial cancer,
making signiﬁcant headway in the prognosis of women
with metastatic disease. Meanwhile, there is a need for an
expedientsecond-linetreatment,andclinicaltrialsshouldbe
encouraged.
Trastuzumab. HER-2 ampliﬁcation or overexpression has
been demonstrated and linked to prognosis in endometrial
cancer as well as in many other cancer types [105, 106].
HER-2/neu overexpression and gene ampliﬁcation were
found in about 20%–30% of serous carcinomas [91]. It
is worth mentioning that in most series overexpression
is more common than ampliﬁcation. Trastuzumab is a
monoclonal antibody to the extracellular domain of the
HER-2 protein. Although HER-2 overexpression observed in
serous carcinoma of the uterus provides a strong biologic
rationale for the use of trastuzumab in the treatment of this
malignancy, a GOG study examining the use of trastuzumab
in women with HER-2 positive endometrial cancer did not
r e p o r ta n ya c t i v i t y[ 107].
4.2.3. Angiogenesis Inhibition. It has been recognised that
VEGF is key to tumour angiogenesis and progression
representing the cornerstone of successful antineoplastic
treatments. Increased levels of VEGF in endometrial cancer
have been correlated with poor outcome. Preclinical models
demonstrate the eﬀectiveness of bevacizumab in combi-
nation with chemotherapy against endometrial cancer cell
lines [108, 109]. Bevacizumab, a recombinant humanized
immunoglobulin monoclonal antibody to vascular endothe-
lial growth factor (VEGF), has proved to be eﬀectiveand well
tolerated in a number of malignancies. A small, retrospective
study reviewed 10 patients with recurrent uterine neoplasms
treated with bevacizumab. Two patients responded to treat-
ment and the disease was stabilized in three patients [110]. A
GOGphaseIItrialofsingle-agentbevacizumabinmetastatic
endometrial cancer has recently been completed, the results
of which should soon be announced (GOG 229-E). VEGF-
Trap is a recombinantly produced fusion protein consisting
of human VEGF receptor extracellular domains fused to the
Fcportionofahumanimmunoglobulinγ (IgG).Itfunctions
as a decoy receptor preventing the VEGF ligand from
interactingwithitsligand.AGOGphaseIItrialofVEGFtrap
in metastatic endometrial cancer is still in progress (GOG
229-F) (reviewed in [80]). A phase II trial of sorafenib, a
tyrosine kinase inhibitor with antiangiogenic activity, has
been completed in the National Cancer Institute’s phase II
network (reviewed in [80]). Preliminary results were not
encouraging. A phase II trial of a second antiangiogenic
tyrosine kinase inhibitor, sunitinib, is underway [111].Obstetrics and Gynecology International 7
4.2.4. Fibroblast Growth Factor Receptor 2 Inhibition. Fibrob-
last growth factor receptor 2 (FGFR2) is regulated on the
basis of the balance of FGFs, heparan-sulfate proteoglycans,
FGFR2 isoforms, endogenous inhibitors, and microRNAs
[112]. The recent identiﬁcation of activating mutations
in FGFR2 in endometrial tumors has generated a new
avenue for the development of targeted therapeutic agents
[113, 114]. The majority of the mutations identiﬁed are
identical to germline mutations in FGFR2 and FGFR3 that
cause craniosynostosis and hypochondroplasia syndromes
andresultinbothligand-independentandligand-dependent
receptor activation [115]. Mutations that predominantly
occur in the endometrioid subtype of endometrial cancer
(16%) are mutually exclusive with KRAS mutation but occur
in the presence of PTEN abrogation [116, 117]. In vitro
studies have shown that endometrial cancer cell lines with
activatingFGFR2mutationsareselectivelysensitivetoapan-
FGFR inhibitor, PD173074 [113]. Oral administration of
AZD2171 or Ki23057 inhibits in vivo proliferation of cancer
cells with aberrant FGFR2 activation in rodent therapeutic
models [112]. Several agents with activity against FGFRs are
currently in clinical trials. Among PD173074, SU5402, and
AZD2171 functioning as FGFR inhibitors, AZD2171 is the
most promising anticancer drug [114]. Investigation of these
agents in endometrial cancer patients with activating FGFR2
m u t a t i o n si sw a r r a n t e d[ 113].
5.Claudines
Epithelial receptors for clostridium perfringens enterotoxin
(CPE), also known as claudines, may well prove to be the
next target therapy for endometrial cancer, especially against
aggressive disease variants. It has been shown that papillary-
serous neoplasms overexpress claudines-1,-3 and -4 [118–
120], while clear-cell ones overexpress claudines -3, and -4
[119]. Overexpression of claudines-3 and -4 could in part
explain the aggressive behaviour of these histologies [119,
121]suggestingtheirpotentialasusefulbiomarkersortargets
for type speciﬁc treatment.
6. Conclusion
Endometrial cancer is the most common gynaecological
cancer in western countries. Although radiotherapy remains
the cornerstone of postoperative management, accumulating
data show that adjuvant chemotherapy may display promis-
ing results after staging surgery. Unfortunately, the prognosis
of patients with metastatic disease remains disappointing
with only-one year survival commonly reported despite
treatment eﬀorts. Progestins remain an eﬀective option,
especially for those patients with low-grade estrogen and/or
progesterone receptor positive disease. Chemotherapy com-
prising paclitaxel, doxorubicin, and cisplatin is beneﬁcial for
patients with advanced or metastatic disease after radical
surgery and potentially for patients with early-stage disease
and high-risk factors. Toxicity is a concern, in which the
development of less toxic regimens such as the combination
of paclitaxel with carboplatin may diminish. In women with
multiple medical comorbidities, single-agent chemotherapy
may be better tolerated and still yield acceptable results. A
betterunderstandingofthemolecularaspectsofendometrial
cancer biology has allowed clinical research to develop
eﬀective and targeted antineoplastic agents (everolimus,
temsirolimus, geﬁtinib, erlotinib, cetuximab, trastuzumab,
bevacizumab, sorafenib). Although targeted therapy is in
general less toxic than chemotherapy, its use may be accom-
paniedinsomeinstancesbyconsiderabletoxicity.Continued
investigation into the molecular pathways of endometrial
cancer development and progression will enhance existing
knowledge of this disease process promoting the discovery
of novel, superior treatment options for patients.
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